Biodesix, Inc. (BDSX)
Automate Your Wheel Strategy on BDSX
With Tiblio's Option Bot, you can configure your own wheel strategy including BDSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BDSX
- Rev/Share 0.5081
- Book/Share 0.0755
- PB 4.3129
- Debt/Equity 5.6316
- CurrentRatio 2.2245
- ROIC -0.4257
- MktCap 47706257.0
- FreeCF/Share -0.3084
- PFCF -1.0554
- PE -1.1802
- Debt/Assets 0.7222
- DivYield 0
- ROE -1.6832
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BDSX | William Blair | Outperform | Market Perform | -- | -- | May 14, 2025 |
| Initiation | BDSX | Scotiabank | -- | Sector Outperform | -- | -- | Sept. 16, 2024 |
News
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st.
Read More
Biodesix to Participate in Upcoming Investor Conferences
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences:
Read More
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Read More
Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025.
Read More
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of trading on Monday, March 3.
Read More
About Biodesix, Inc. (BDSX)
- IPO Date 2020-10-28
- Website https://www.biodesix.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Scott Hutton
- Employees 273